BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Moderna Makes Headway with COVID-19 Booster, Flu Vaccine

  Moderna announced its Omicron-containing COVID-19 booster candidate, mRNA-1273.214, demonstrated superior antibody response against Omicron in its Phase II/III study.

  June 8, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  FTC Probes Prescription Drug Middlemen as Drug Prices Soar

  Calls for a reform of drug prices have become a regular occurrence, particularly in the midst of political campaigns. Yet a new report shows the median price of a new drug launched in 2021 was $180,000.

  June 8, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Vertex Kidney Disease Drug Scores FDA Breakthrough Therapy Designation

  The FDA granted Breakthrough Therapy Designation to Verttex’s candidate inaxaplin (VX-147). for the treatment of APOL1-mediated focal segment glomerulosclerosis.

  June 8, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Sanofi Celebrates Latest Dupixent Approval, Cambridge Crossing Opening

  The approval expands the rapidly growing number of indications for Dupixent, which is the first and only biologic medication with the FDA’s nod to treat atopic dermatitis from infancy to adulthood.

  June 8, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  AstraZeneca’s Evusheld Successfully Prevents Progression to Severe COVID-19

  Results of the Phase III trial showed that Evusheld protected against progression to severe COVID-19 or death in the early outpatient treatment of mild-to-moderate COVID-19.

  June 8, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Mineralys Therapeutics Rakes in $118M for Hypertension Therapy

  Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing a best-in-class, novel therapy for high blood pressure, closed a $118 million Series B investment round.

  June 8, 2022

   · 

  2 min read

   · 

  Paolo Besabella
• 

  Business

  Actor Greg Grunberg Discusses New Series: “The Care Giver”

  Greg Grunberg, who has appeared in multiple Star Wars projects, has partnered with Jazz Pharmaceuticals to bring “The Care Giver”, a video web series, to life.

  June 8, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Annexon Engages the Target, Sees Stabilization in Phase II Huntington’s Trial

  Annexon released final data from an open-label phase II clinical trial, showing that its drug candidate ANX005 safely stabilized disease progression in patients with Huntington’s disease.

  June 8, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  PMV, Genmab, Seagen & More Present New Clinical Data at ASCO

  More oncology firms presented positive developments in their respective cancer research programs at the 2022 ASCO annual meeting this week.

  June 8, 2022

   · 

  5 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Ensysce’s Novel Opioid Appears Impervious to Abuse

  Ensysce Biosciences is developing solutions that make opioids safer, and virtually impossible to abuse. BioSpace spoke with CEO Lynn Kirkpatrick about the company’s novel technology.

  June 8, 2022

   · 

  4 min read

   · 

  Gail Dutton